Healthcare industry

Smallest 3D printed miniature endoscope in the world detects cholesterol plaques and thrombs inside human and mouse arteries.

Microstructure Technology - 17/07/2020

An electronic nose for many applications

Sensory organs are sophisticated masterpieces of nature. That is why humans have often tried to copy them. Be it cameras or microphones - there are technical objects that have always been based on natural models such as the eye or the ear. For a long time, however, no artificial sense of smell has featured in the technical repertoire. Now researchers at the Karlsruhe Institute of Technology (KIT) have developed an electronic nose. It can…

Vaccine development - 02/06/2020

CureVac as a pioneer of mRNA technology – what is behind the novel COVID-19 vaccine?

All eyes are on vaccines against the coronavirus. The Tübingen-based company CureVac is doing pioneering work in this field, and intends to initiate clinical testing of its lead vaccine candidate in June. At the same time, Curevac is manufacturing the material for this vaccine candidate. But that’s not all: the novel mRNA technology also has the potential to revolutionise the treatment of cancer and metabolic diseases. What makes the method so…

Multiple sclerosis - 12/03/2020

Direct application of biopharmaceuticals through the nose into the brain

There is currently no cure for multiple sclerosis, the most common neurological autoimmune disease in humans. Biopharmaceuticals that can delay the course of the disease or diminish its effects are often prevented from being fully effective by the blood-brain barrier. A European consortium led by the Fraunhofer IGB, Stuttgart is developing a new technology that can transport an innovative active ingredient directly to the central nervous system.

Article - 08/11/2019

Nanorobots as future minimally invasive tools for the eye

It is difficult to place drugs in the right place in the eye. When using droplets, only a small fraction of the drug reaches its target. Injecting drugs into the eye is also more a matter of luck than judgement. Basic researchers at the Max Planck Institute for Intelligent Systems Stuttgart have developed a nanorobot that can be loaded with active ingredients for treating eye diseases and directed through the solid tissue of the vitreous body.

Article - 07/02/2019

Artificial intelligence in ophthalmology

Retinal diseases such as age-related macular degeneration (AMD) are now treatable. However, it is hard to predict individual disease progression. A group of researchers at the University Eye Centre in Freiburg are currently developing a new system which is hoped will allay fears and improve therapy planning. The system uses artificial intelligence to predict therapeutic outcome from image and patient data. Initial results are already available.

Article - 21/08/2018

Parkinson's disease: vitamin B3 has a positive effect on nerve cells

Parkinson's disease is one of the most common neurodegenerative diseases in the world. There are around 4.1 million sufferers worldwide. It is characterised by motor impairments that result from the death of certain nerve cells in the brain. Researchers at the University of Tübingen have now discovered that vitamin B3 has a positive effect on damaged nerve cells and can boost their energy metabolism.

Article - 13/06/2018

TeleDerm: Rapid help from a dermatologist via teleconsultation

Some geographical locations have relatively few specialist medical practices. Getting an appointment with a specialist if you live in such areas might mean a long wait or a long journey. A study being carried out at the University of Tübingen is looking to improve this situation: the TeleDerm project involves dermatologists using telemedicine to assess skin disorders from images taken by GPs.

Big Data - 13/03/2018

“More data does not automatically imply more knowledge“

In Germany, one of the big names in evidence-based medicine is Prof. Dr. rer. nat. Gerd Antes, co-director of Cochrane Germany. In the following interview, Antes talks about the hype surrounding big data, warns against false promises and reminds us about what is taken for granted.

Article - 14/02/2018

Animal-free diabetes research with the pancreas chip

Quite a number of promising drug candidates for the treatment of diabetes are currently in the pharmaceutical pipeline, including innovative drugs that can stimulate the regeneration of insulin-producing pancreatic cells. However, they will have to be safety tested in animals. Scientists from Ulm University Hospital have now begun to develop a pancreatic chip from stem cells.

Company profile - 04/09/2017

Mireca: a new drug for stopping the progression of eye diseases

A team of researchers from several EU countries has developed a new drug that stops the progression of hereditary retinal diseases. The project partners founded a company called Mireca Medicines GmbH in the city of Tübingen to bring the drug to market.

Press release - 06/04/2017

Start-up in the garage – a location with prospects

Newly established start-up wins award – Mireca Medicines GmbH develops treatment for hereditary eye disease and receives Innovation Award of the biotechnology regions in Germany

Company profile - 09/01/2017

Novaliq to develop innovative eye drop products

A remedy is now available for people suffering from dry eye disease. Novaliq GmbH, a specialty pharmaceuticals company from Heidelberg, has developed a highly innovative technology platform for producing innovative drugs to eliminate common eye conditions that cause itching, burning and a feeling of pressure on the eye. The new drug delivery platform not only opens up groundbreaking new prospects for ophthalmology, but also for dermatology.

Article - 08/11/2016

Towards at-home genetic testing

The ability to detect a broad range of conditions and modifications in human, animal, plant and pathogen genes is highly important in the field of medicine for diagnosing diseases and starting therapy as quickly as possible. Chemists at the University of Konstanz have now developed a genetic test that does not need to be carried out in the laboratory and can be evaluated with the naked eye, similar to a pregnancy test. The test would therefore be…

Article - 10/10/2016

Teva plans the large-scale production of monoclonal antibodies in Ulm

Teva is investing heavily in its biotechnological production site in Ulm. On behalf of BIOPRO Baden-Württemberg, Walter Pytlik spoke with Dr. Hermann Allgaier, CEO of Teva Biotech, about the importance of biotechnology for the Group and about Teva in general. The company is headquartered in Israel.

Article - 08/08/2016

First achromatopsia gene therapy clinical trial in Germany is going well

Around 3000 people suffer from achromatopsia in Germany. Achromatopsia is an inherited visual disorder characterised by the absence of full colour vision. The disease is caused by a genetic defect that makes the retina's cone photoreceptors, needed for daylight and colour vision, non-functional. There is currently no cure for achromatopsia. Scientists from Tübingen University Hospital and their colleagues from Munich and New York have now…

Article - 06/06/2016

ZEISS Vision Science Lab: understanding vision

Carl Zeiss AG and the University of Tübingen have been jointly running the ZEISS Vision Science Lab since 2013. This is a workgroup that is both fully integrated into research as well as delivering results for the development and improvement of products. The “Industry on Campus” professorship shows how different interests can turn out successfully for both parties involved.

Article - 24/03/2016

Retrospective: Meet & Match "Optical Imaging: Future Trends in Medical Applications"

The Meet & Match event “Optical Imaging: Future Trends in Medical Applications” – organised by BIOPRO Baden-Württemberg GmbH and the Fraunhofer Project Group for Automation in Medicine and Biotechnology (PAMB) in Mannheim on 9th March 2016 - attracted around 80 participants. Interesting lectures provided in-depth insights into future trends in optical imaging in medical applications.

Article - 18/01/2016

New approaches in the life sciences industry: innovative strategies for courageous companies

For many years, the pharmaceutical industry has been investing increasing amounts of money in the development of new products. Dr. Friedemann Taut, a specialist in anaesthesia, intensive care, emergency medicine and clinical pharmacology as well as founder and managing director of Taut Science & Service Ltd. a consultanca for Medical Device and Drug Development, explains in the following interview why small- and mid-sized companies can stay a…

Article - 16/12/2015

Small and handy – tiny LED lights can improve eye surgeons’ work

A new lighting system for vitreoretinal surgery that uses small white light-emitting diode (LED) technology, promises to be safer for patients and more practical for surgeons. It will probably be three years before the idea is launched as a medical product. Prototypes need to be optimised, approved and then tested for safety and functionality at the University Eye Hospital in Frankfurt.

Article - 04/12/2015

Exploring the retinal code

Dr. Philipp Berens from the Bernstein Center for Computational Neuroscience at the University of Tübingen uses computer models to study how light that enters the retina is turned into events that trigger nerve impulses. The bioinformatician has recently received the BMBF’s Bernstein Award for Computational Neuroscience.

Article - 05/10/2015

Nanoparticles make eye drops more effective

Drops are a common way of applying drugs for treating a wide of range of eye diseases. Most of us have used eye drops at least once in our lives, but we are not usually aware that even if the drops are applied correctly, only one percent of the drug reaches the eye. The rest is flushed out by eyelid movement or with tear fluid. So very high drug concentrations are needed, and the downside of this is that it can cause substantial adverse effects.…

Article - 02/02/2015

Rentschler Biotechnologie invests in new production plant

The Laupheim-based contract manufacturer Rentschler Biotechnologie GmbH is greatly expanding its production capacities. The company is investing €24 million in the construction of two 3,000 litre stainless steel bioreactors, which should be operational in early 2017 and will more than double the production capacities for cell culture-derived proteins. Rentschler also announced recently that it was adding a new 2,000 litre single-use bioreactor…

Guest article - 19/01/2015

Rich in contrasts – three research months in Shanghai

After graduating, Johannes Zang applied for a Baden-Württemberg Ministry of Science, Research and the Arts China Scholarship to spend three months in Shanghai before going on to do his PhD. At the Shanghai Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences, he was, amongst other things, involved in elucidating the crystal structures of proteins. He also had time to learn about the city of Shanghai, China and the Chinese…

Guest article - 05/01/2015

Experience report: an internship in Qingdao

Nicole Kattner spent six months at the Institute of Bioenergy and Bioprocess Technology in Qingdao, a city in the coastal province of Shandong in the East China region. Nicole’s stay in China was made possible by a grant from the Baden-Württemberg Ministry of Science, Research and the Arts. Besides gaining first-hand experience in a Chinese laboratory during the week, she used public holidays and work-free weekends to travel around and learn…